Genotoxicity of retroviral hematopoietic stem cell gene therapy.

Abstract

INTRODUCTION:

Retroviral vectors have been developed for hematopoietic stem cell (HSC) gene therapy and have successfully cured X-linked severe combined immunodeficiency (SCID-X1), adenosine deaminase deficiency (ADA-SCID), adrenoleukodystrophy, and Wiskott-Aldrich syndrome. However, in HSC gene therapy clinical trials, genotoxicity mediated by integrated vector proviruses has led to clonal expansion, and in some cases frank leukemia. Numerous studies have been performed to understand the molecular basis of vector-mediated genotoxicity with the aim of developing safer vectors and safer gene therapy protocols. These genotoxicity studies are critical to advancing HSC gene therapy.

AREAS COVERED:

This review provides an introduction to the mechanisms of retroviral vector genotoxicity. It also covers advances over the last 20 years in designing safer gene therapy vectors, and in integration site analysis in clinical trials and large animal models. Mechanisms of retroviral-mediated genotoxicity, and the risk factors that contribute to clonal expansion and leukemia in HSC gene therapy are introduced.

EXPERT OPINION:

Continued research on virus-host interactions and next-generation vectors should further improve the safety of future HSC gene therapy vectors and protocols.

• Authors: Grant D Trobridge
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 11 Issue 5 Pg. 581-93 (May 2011) ISSN: 1744-7682 [Electronic] England
• PMID: 21375467 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Topics

• Animals
• Clinical Trials as Topic
• Genetic Therapy (adverse effects)
• Genetic Vectors (toxicity)
• Hematopoietic Stem Cell Transplantation
• Humans
• Mutagenesis, Insertional
• Retroviridae (genetics)
• X-Linked Combined Immunodeficiency Diseases (therapy)